Gut Microbiota Dysbiosis Associated with Bile Acid Metabolism in Neonatal Cholestasis Disease

Sci Rep. 2020 May 6;10(1):7686. doi: 10.1038/s41598-020-64728-4.

Abstract

Neonatal cholestasis disease (NCD) is a complex and easily mis-diagnosed condition. We analyzed microbiota community structure in feces and measured short-chain fatty acids, bile acids (BAs) and liver function of 12 healthy, 13 NCD, and 13 treated infants after diagnosis. Based on 16S rRNA gene amplicon sequencing and gas-chromatographic-mass-spectrometric analysis of secondary BAs, we identified microbial genera and metabolites that associate with abnormal bile secretion. Streptococcus gallolyticus and Parabacteroides distasonis, and Lactobacillus gasseri had higher relative abundance in healthy and NCD infants respectively. Compared to NCD patients, healthy infants had higher LCA, CDCA and GCDCA fecal concentrations. The three microbial species and three secondary bile acids were selected as potential non-invasive combined biomarkers to diagnose NCD. We propose that microbiota-metabolite combined biomarkers could be used for diagnosis of NCD, and this may contribute to improved early clinical diagnosis of NCD in the future.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Bile Acids and Salts / metabolism*
  • Biomarkers
  • Cholestasis / diagnosis
  • Cholestasis / etiology*
  • Cholestasis / metabolism*
  • Disease Susceptibility
  • Dysbiosis*
  • Feces / microbiology
  • Gastrointestinal Microbiome*
  • Humans
  • Infant
  • Infant, Newborn
  • Liver / metabolism
  • Liver Function Tests
  • Metagenome
  • Metagenomics / methods
  • Prognosis

Substances

  • Bile Acids and Salts
  • Biomarkers